Observational analysis identifies specific vascular and lymphatic adverse events in patients, indicating potential risks linked to antiangiogenic therapy.
Key Points
Antiangiogenic therapy is linked to significant vascular and lymphatic adverse events that require careful monitoring.
Disproportionality analysis revealed drug-specific risks, with hypertension and hemorrhage being major concerns.
Using data from WHO‐VigiAccess ensured a comprehensive evaluation of FDA-approved agents in real-world settings.
Findings highlight the need for personalized clinical use of antiangiogenic drugs to improve patient safety.